MARKET COMPOSITE
HROW - Harrow Health Inc8:00:00 PM 3/27/2024
Price
$12.73
+ 0.15 (1.19%)
Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, TN. The change of name to Harrow Health in January 2019 reflected a goal of "creating, investing in, operating and growing a diversified portfolio of health care businesses that meet the needs of health care providers and patients across America", according to CEO Mark Baum.
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue36.4MM+6%
Gross Profit25.1MM+4%
Cost Of Revenue11.3MM+12%
Operating Income-4.9MM-380%
Operating Expenses29.9MM+33%
Net Income-9.1MM-
R&D3.3MM-
G&A26.2MM+25%
Amortization2.4MM-5%
Interest Expense5.1MM-11%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript March 20, 2024 Harrow Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to Harrow’s Fourth Quarter and Year-End 2023 Earnings Conference Call. My name is […]

    Adjusted EBITDA Soars as Harrow Inc (HROW) Navigates Market Challenges

    NASHVILLE, Tenn., March 19, 2024--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also posted its fourth quarter and year-end Letter to Stockholders and corporate presentation to the "Investors" section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period as well as

    Wasatch Global Investors, an asset management company, released its “Wasatch Micro Cap Value Strategy” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy posted a double-digit gain in the fourth quarter but trailed the benchmark Russell Microcap Index which rose 16.06%. In 2023, the strategy appreciated and outperformed the benchmark’s […]

    NASHVILLE, Tenn., March 05, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Wednesday, Ma

    SRK Capital, an investment management firm, released its fourth quarter 2023 investor letter. A copy of the same can be downloaded here. In 2023, the SRK Fund appreciated 17.15% while the S&P 500 and the Russell 2000 appreciated 26.29% and 16.93%, respectively. The fund increased 869.94% compared to 98.88% and 41.75% for the indexes respectively. […]

    NASHVILLE, Tenn. & TORONTO, February 15, 2024--Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. ("Apotex"), Canada’s largest pharmaceutical company, today jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter (OTC) Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®.

    NASHVILLE, Tenn., January 29, 2024--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to the Company’s Board of Directors, effective immediately. Harrow’s Board now consists of six members.

    NASHVILLE, Tenn., January 11, 2024--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) dosed prescription drug based on a "water‑free" semifluorinated alkane eyedrop technology, is now available in the U.S. – and includes a 100% Money‑Back Guarantee program. VEVYE, uniquely dispensed in a 10 microliter drop, is the first and only cyclosporine‑based product indicate

    NASHVILLE, Tenn., January 03, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today provided a corporate update. The Company previously announced that MELT-300 achieved the primary sedation endpoint in its Phase 2 Pivotal Efficacy and Safety Study in subjects undergoing cataract surgery. MELT‑300, a non-IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg), is administered sub